Brii Biosciences Limited
腾盛博药生物科技有限公司
(Incorporated in the Cayman Islands with limited liability)
(Stock Code: 2137)

VOLUNTARY ANNOUNCEMENT
NEW DATA FROM PARTNERS AT EASL CONGRESS 2023

This announcement is made by the board of directors (the "**Board**") of Brii Biosciences Limited (the "**Company**") on a voluntary basis.

The Board is pleased to announce today that the Company's strategic partners, Vir Biotechnology, Inc. ("**Vir**") and VBI Vaccines, Inc. ("**VBI**"), presented results from multiple clinical studies for the treatment and prevention of chronic hepatitis B viral ("**HBV**") infection at the European Association for the Study of the Liver ("**EASL**") Congress 2023 that further support the clinical evaluation of assets of the Company as a potential best-in-class functional cure for chronic HBV infection.

"In concert with our partners, we look forward to leveraging these exciting insights gained from the trials to progress our scientific approach," said Dr. David Margolis, MD, the Infectious Disease Therapeutic Area Head of the Company, "by design, we have intentionally crafted our HBV portfolio with the ability to explore multiple novel combination treatments to improve the probability of achieving a high rate of functional cure for broad HBV patient populations, and we remain committed to driving scientific innovation on behalf of these patients."

In a late-breaker oral presentation, Vir announced 24-week follow-up data from a Phase 2 trial that demonstrated when VIR-2218 (BRII-835) was given for 24 or 48 weeks on top of a course of up to 48 weeks of pegylated interferon alpha ("**PEG-IFN-α**"), 26% (8/31) of virally suppressed participants with chronic HBV achieved hepatitis B surface antigen ("**HBsAg**") loss at end of treatment. In particular:

- 16% (5/31) of participants demonstrated sustained HBsAg loss 24 weeks after end of treatment. Two of the five participants had baseline HBsAg levels greater than 1,000 IU/mL. No new safety findings were observed during the follow-up.

- Four participants with anti-HBsAg antibodies ("**anti-HBs**") titers greater than 500 mIU/mL at the end of treatment achieved a sustained HBsAg loss at 24 weeks after the end of treatment suggesting the potential use of anti-HBs titers as an on-treatment biomarker of off-treatment sustained response.

In another oral presentation, Vir announced 48-week post-treatment data from Part A of the Phase 2 Monoclonal Antibody siRNA Combination against Hepatitis B trial. VIR-2218 (BRII-835) and VIR-3434 (BRII-877) as combination treatment for chronic HBV infection resulted in 2.7-3.1 $\log_{10}$ IU/mL decrease in HBsAg levels following five or 12 weeks of combination treatment with 90% of participants achieving HBsAg less than 10 IU/mL at the end of this short treatment. In particular:

- The majority of participants met the criteria for discontinuing nucleotide reverse transcriptase inhibitor ("**NRTI**") therapy because they achieved all of the following: HBsAg less than 100 IU/mL and at or greater than 1 $\log_{10}$ IU/mL reduction from baseline HBsAg level; HBV deoxyribonucleic acid below the lower limit of quantification; and Hepatitis B Envelope Antigen-negative and Alanine aminotransferase at or less than twice the upper limit of normal. 67% (4/6) of those participants remained off NRTI therapy as of the last available follow up.

- Combination treatment with VIR-2218 (BRII-835) and VIR-3434 (BRII-877) was generally well tolerated and associated primarily with mild adverse events. All treatment-related adverse events were Grade 1, with no study discontinuations.

In a poster presentation, Vir highlighted the single dose pharmacokinetics of VIR-3434 (BRII-877) from a Phase 1 clinical trial in patients with chronic HBV infection, with data supporting continued evaluation of VIR-3434 (BRII-877). In particular:

- The highest and most durable free VIR-3434 (BRII-877) exposure was observed with the 300 mg dose, regardless of baseline HBsAg level. Other doses evaluated include 6 mg, 18 mg and 75 mg.

- VIR-3434 (BRII-877) has a shorter terminal half-life and was cleared faster in participants with higher baseline HBsAg.

In addition, VBI presented follow-up data in a subset of participants from the pivotal Phase 3 study, PROTECT, up to 3.5 years after completion of immunization with PreHevbrio®, a prophylactic 3-antigen HBV vaccine, to determine the magnitude and duration of immune response. PreHevbrio consists of the same recombinant HBV surface antigens, Pre-S1, Pre-S2 and S, in virus-like particles, used in BRII-179 (VBI-2601). In particular:

- At all measured timepoints, participants immunized with PreHevbrio had significantly higher ($P<0.0001$) mean HBsAg antibody titers as compared to those who were immunized with Engerix-B®.

- The data highlight that PreHevbrio induced T-cell responses against Pre-S1 and Pre-S2 proteins that correlated with high anti-HBs titers.

- At 3.5 years follow up, the mean anti-HBs titers in participants vaccinated with PreHevbrio were 5.1x higher than those vaccinated with Engerix-B (1287.2 vs. 253.7 mIU/mL) suggesting that T-cell responses of PreHevbrio may contribute to long lasting and strong humoral immune responses and greater durability compared with Engerix-B.

As part of the Company's unique approach to develop a functional cure for HBV, the Company and its partners are progressing multiple studies, including BRII-835 (VIR-2218) and BRII-179 (VBI-2601) combination, BRII-179 and PEG-IFN-α combination, BRII-835 (VIR-2218), BRII-877 (VIR-3434) with or without PEG-IFN-α, and BRII-835 (VIR-2218) and/or BRII-877 (VIR-3434) in combination with other agents. To date, approximately 390, 240 and 180 subjects have been treated with BRII-835 (VIR-2218), BRII-877 (VIR-3434), and BRII-179 (VBI-2601), respectively.

Cautionary Statement: There is no assurance that BRII-179, BRII-835, BRII-877 and PreHevbrio will ultimately be successfully developed or marketed by the Company. Shareholders of the Company and potential investors are advised to exercise caution when dealing in the shares of the Company. When in doubt, shareholders of the Company and potential investors are advised to seek advice from professional or financial advisers.

By order of the Board
Brii Biosciences Limited
Dr. Zhi Hong
Chairman

Hong Kong, June 25, 2023

As at the date of this announcement, the Board comprises Dr. Zhi Hong and Dr. Ankang Li as executive directors; Mr. Robert Taylor Nelsen as non-executive director; and Dr. Martin J Murphy Jr, Ms. Grace Hui Tang, Mr. Yiu Wa Alec Tsui, Mr. Gregg Huber Alton and Dr. Taiyin Yang as independent non-executive directors.